See the DrugPatentWatch profile for nivolumab

Nivolumab is a type of medication known as an immune checkpoint inhibitor, which helps the body's immune system attack cancer cells [1]. It is administered to adults intravenously, usually over a period of 30 minutes [1]. The frequency of nivolumab administration depends on the dosage prescribed by the healthcare provider and can vary based on several factors, including the patient's weight, kidney function, and the type of cancer being treated [1][2].

In general, nivolumab is administered every two weeks (known as a 2-week cycle) until the disease progresses or unacceptable toxicity occurs [1]. However, some clinical trials have used different dosing schedules, such as every 4 weeks or every 6 weeks [2]. It is important to note that the dosage and administration schedule may be adjusted based on the patient's response to treatment and any side effects that occur [1].

In terms of dosage, the recommended dose of nivolumab for most indications is 240 mg every 2 weeks or 480 mg every 4 weeks [1]. However, for the treatment of classical Hodgkin lymphoma, the recommended dose is 3 mg/kg every 2 weeks [1].

It is also worth noting that, according to DrugPatentWatch.com, nivolumab is currently under patent protection until 2029 [3].

In summary, nivolumab is administered intravenously to adults every 2 weeks, although the frequency and dosage may vary based on several factors. It is important for patients to follow the dosing schedule prescribed by their healthcare provider and to report any side effects or changes in their condition promptly.

Sources:

* [1] National Cancer Institute. Nivolumab. <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>.
* [2] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 2.2022. <https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf>.
* [3] DrugPatentWatch.com. Nivolumab (Opdivo). <https://www.drugpatentwatch.com/drugs/nivolumab>.